Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study

Odilson M Silvestre1, Alexandra Gonçalves1,2, Wilson Nadruz1,3

  • 1Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

Insights

Both low and high ferritin levels, indicating iron imbalance, increase heart failure risk in the general population. This association persists even without anemia, suggesting iron

Area of Science:

  • Cardiology
  • Hematology
  • Epidemiology

Background:

  • Iron overload is linked to cardiac damage.
  • Iron deficiency is associated with poorer outcomes in heart failure (HF) patients.
  • The role of iron status in incident HF within the general population is unclear.

Purpose of the Study:

  • To investigate the relationship between serum ferritin levels and the incidence of heart failure.
  • To examine the impact of both low and high ferritin levels on HF risk.

Main Methods:

  • Analysis of 1063 participants from the Atherosclerosis Risk in Communities (ARIC) Study, free of HF at baseline.
  • Serum ferritin levels measured at baseline (1987-1989) and categorized as low, normal, or high.
  • Multivariable Cox proportional hazards models used to assess incident HF over a 21-year follow-up.

Main Results:

  • A total of 144 participants developed HF during follow-up.
  • Low ferritin levels were associated with a significantly higher risk of incident HF (HR=2.24, P=0.02).
  • High ferritin levels also showed a higher risk of incident HF (HR=1.81, P=0.04).
  • The association between low ferritin and incident HF remained significant even after excluding participants with anemia (HR=2.28, P=0.03).

Conclusions:

  • Both low and high serum ferritin levels are linked to an increased risk of developing heart failure in the general population.
  • Iron imbalance, indicated by ferritin levels, may contribute to heart failure development, independent of anemia.
  • These findings highlight the importance of monitoring iron status in cardiovascular health.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
509
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
681
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
493